2020
Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure
Murphy K, Chipps B, Beuther D, Wise R, McCann W, Gilbert I, Eudicone J, Gandhi H, Harding G, Coyne K, Zeiger R, Board P, Kobernick A, Mohammad A, Cherry A, Fein A, Gaines A, Ramsey A, Michaud A, Palmer A, Kim A, Smith A, White A, Ricci A, Kettelhut B, Modena B, Stone B, Rolston B, Schnapf B, Krajicek B, Kraft C, Hopkins C, Natalie C, Anderson C, Czajkowski C, Arce D, Hamlin D, Hill D, Mares D, Pham D, Liao D, Simmons D, Johnson D, Jhaveri D, Maselli D, Kerwin E, Schuman E, Sher E, Bleecker E, Rakowski E, Hsu F, Averill F, Barsanti F, Gross G, Chupp G, Head G, Nasir H, Lee H, Barjaktarevic I, Cook J, Krainson J, Pearl J, Bellak J, Perez-Fernandez J, Rehm J, Trevor J, Most J, Hanson J, Blessing-Moore J, Biller J, Gedell J, Southard J, Chancellor J, Ilowite J, Romeo J, Mercado J, Fisher J, Greiwe J, Gregory K, Nadeau K, Shenoy K, Tan L, Stefanowicz L, Humes L, Bowers L, O’Connor M, Perez M, White M, Hegewald M, Wilson M, Sikora M, Morganroth M, Smith M, Farooqui N, Lesch N, Jain N, Parikh N, Hartog N, Luthin P, Stewart P, O’Connor P, Schochet P, Goldberg P, Patel P, Chinthrajah R, Sidhu R, Ayinla R, Brown R, Stadtler R, Wachs R, Balkissoon R, Duplantier R, Puente R, Settipane R, Mustafa S, Surani S, Jawad S, Adams S, Villegas S, Al-Farra S, Subramanian S, Bains S, Kelsen S, Wise S, Estrella-Eades S, Smith S, Qureshi T, Chen T, Kelbel T, Miller T, Jain V, Soong W, Soler X, Mattar Z. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2263-2274.e5. PMID: 32387166, DOI: 10.1016/j.jaip.2020.02.042.Peer-Reviewed Original ResearchConceptsAsthma controlAsthma Control Test scoresAsthma control toolPhysician-diagnosed asthmaCut pointsLogistic regression analysisAsthma impairmentExacerbation historyAsthma severityFuture exacerbationsTest-retest reliabilityRisk QuestionnaireSymptom impairmentAsthmaSpecialty practicePatientsRisk questionsGlobal InitiativeImpairmentAirQRisk increaseCharacteristic curveExacerbationRegression analysisComposite measure
2011
Targeting ST2L Potentiates CpG-Mediated Therapeutic Effects in a Chronic Fungal Asthma Model
Ramaprakash H, Shibata T, Duffy KE, Ismailoglu UB, Bredernitz RM, Moreira AP, Coelho AL, Das AM, Fursov N, Chupp GL, Hogaboam CM. Targeting ST2L Potentiates CpG-Mediated Therapeutic Effects in a Chronic Fungal Asthma Model. American Journal Of Pathology 2011, 179: 104-115. PMID: 21640974, PMCID: PMC3123853, DOI: 10.1016/j.ajpath.2011.03.032.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAspergillosis, Allergic BronchopulmonaryAspergillus fumigatusAsthmaBlotting, WesternBronchial HyperreactivityCase-Control StudiesChemokine CXCL9Chronic DiseaseDisease Models, AnimalEnzyme-Linked Immunosorbent AssayFemaleFibrosisHumansImmunoenzyme TechniquesImmunoglobulin GLungMiceMice, Inbred C57BLOligodeoxyribonucleotidesReceptors, Interleukin-1Reverse Transcriptase Polymerase Chain ReactionRNA, MessengerToll-Like Receptor 9ConceptsAsthmatic miceExperimental asthmaDendritic cellsTherapeutic effectDay 28Live A. fumigatus conidiaControl dendritic cellsMucus cell metaplasiaKey pathological featureCell-associated receptorsA. fumigatus conidiaProtein expression levelsAirway hyperresponsivenessCXCL9 levelsFungal asthmaPeribronchial fibrosisAsthma modelIL-12p70Time-dependent mannerAllergic inflammationAsthma severityCell metaplasiaIL-33Therapeutic blockadeC57BL/6 mice